Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006013
Status:
COMPLETED
Last Update Posted:
2013-07-11
First Post:
2000-07-05
Brief Title:
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Study Overview
Official Title:
Phase II Trial of SU5416 as Treatment for RefractoryRelapsed Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells
PURPOSE Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma
PURPOSE Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma
Detailed Description:
OBJECTIVES I Determine the response rate and response duration of patients with refractory or relapsed multiple myeloma treated with SU5416 II Determine the toxicity of SU5416 in this patient population
OUTLINE This is a multicenter study Patients receive SU5416 IV over 1 hour twice weekly Treatment continues in the absence of unacceptable toxicity or disease progression Patients are followed for survival
PROJECTED ACCRUAL A total of 20-38 patients will be accrued for this study within 2 years
OUTLINE This is a multicenter study Patients receive SU5416 IV over 1 hour twice weekly Treatment continues in the absence of unacceptable toxicity or disease progression Patients are followed for survival
PROJECTED ACCRUAL A total of 20-38 patients will be accrued for this study within 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-58 | OTHER_GRANT | NCI | None |
| CDR0000068022 | REGISTRY | None | None |